Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Liv1-adc pd-1 synergistic modulation: MerckRecent Research Landscape

Tumor immune evasion and systemic toxicity from non-localized T-cell activation drive treatment failure. These engineered constructs bridge specific tumor antigens with costimulatory receptors to restrict immune activation to the microenvironment.

What technical problems is Merck addressing in Liv1-adc pd-1 synergistic modulation?

Insufficient antitumor immune response

(28)evidences

Low therapeutic efficacy in patients with specific genetic mutations or resistant tumor microenvironments. Overcoming this limitation increases survival rates through enhanced immune activation.

Insufficient immune response activation

(11)evidences

Standard monotherapies fail to overcome tumor-induced immunosuppression and limited antigen presentation. Combining targeted cytotoxicity with checkpoint inhibition addresses the failure of the immune system to recognize and eliminate resistant malignant cells.